INTU vs MRK: Which Is the Better Buy?
Side-by-side comparison of Intuit Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Intuit Inc. · Technology
$396.57
+37.7% upside to fair value
High Conviction
Grade A-
VS
Merck & Co., Inc. · Healthcare
$121.42
-2.9% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
INTU has more upside to fair value
(+37.7%).
MRK trades at a lower forward P/E
(14.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTU |
MRK |
| Current Price |
$396.57 |
$121.42 |
| Fair Value Estimate |
$546.00 |
$118.00 |
| Upside to Fair Value |
+37.7%
|
-2.9%
|
| Market Cap |
$110.4B |
$300.2B |
| Forward P/E |
19.5x
|
14.0x
|
| EV / EBITDA |
19.0x
|
11.8x
|
| Price / Sales |
5.9x
|
4.1x
|
| Price / FCF |
18.1x
|
21.4x
|
| Revenue Growth YoY |
+15.6%
|
+1.3%
|
| Gross Margin |
80.8%
|
81.5%
|
| Operating Margin |
26.1%
|
41.2%
|
| Return on Equity |
19.6%
|
34.7%
|
| Dividend Yield |
1.17% |
3.1% |
| FCF Yield |
5.51%
|
4.7%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Intuit is a near-monopoly financial operating system for 60+ million American households and small businesses. TurboTax handles 40%+ of US e-filed returns; QuickBooks is so deeply embedded in SMB workflows it has become the default accounting standard. The stock has fallen 51% from its 2025 high as markets price in AI disruption that has not materialized at scale and may not, since tax complexity…
Merck is a top-5 global pharmaceutical company generating $65B in annual revenue with 81.5% gross margins and 28% net margins. Keytruda, the world's best-selling drug at $31.7B (49% of pharma revenue), faces patent expiry in 2028. Merck is aggressively building replacements through M&A and pipeline launches: Winrevair ($1.4B year one), Capvaxive ($759M), and the $6.7B Terns acquisition for TERN-7…
Accumulation Zones
| Metric |
INTU |
MRK |
| Zone Low |
$410.00 |
$88.00 |
| Zone High |
$464.00 |
$100.00 |
| In Buy Zone? |
Yes
|
No
|